A Phase II, Randomized, Multi-centre Study of Cabazitaxel Versus Abiraterone or Enzalutamide in Poor Prognosis-metastatic Castration-resistant Prostate Cancer
The purpose of this study is to assess and compare the clinical benefit rate in patients
with metastatic castrate-resistant prostate cancer and poor prognostic factors treated with
cabazitaxel or novel hormonal agents (abiraterone or enzalutamide) as initial therapy, to
determine which treatment is most active in this population. Clinical benefit rate is
defined as PSA or measurable radiological response of any duration or stable disease for >
or equal to 12 weeks, in the absence of other indicators of progression.
There is option to cross-over onto the other arm if the patient progresses.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society